A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Neomycin Sulfate, Polymyxin B and Hydrocortisone (NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE)

Neomycin Sulfate, Polymyxin B and Hydrocortisone reduces inflammation and suppresses immune responses, used across many conditions.

First FDA approval1996-08-28
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$4.04/unit
3 NDCs benchmarked, lowest of all strengths.
Average NADAC
$9.03
Across all dosage forms in distribution.
Highest NADAC
$19.02
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Neomycin Sulfate, Polymyxin B and Hydrocortisone used for?

Neomycin Sulfate, Polymyxin B and Hydrocortisone reduces inflammation and suppresses immune responses, used across many conditions.

Is there a generic for Neomycin Sulfate, Polymyxin B and Hydrocortisone?

No. Neomycin Sulfate, Polymyxin B and Hydrocortisone is brand-only with no generic equivalents currently in market.

How much does my plan pay for Neomycin Sulfate, Polymyxin B and Hydrocortisone?

Across 329 Part D plans, Neomycin Sulfate, Polymyxin B and Hydrocortisone averages $9.03/unit (NADAC). Lowest available: $4.04/unit. Highest in distribution: $19.02/unit.

Is Neomycin Sulfate, Polymyxin B and Hydrocortisone on the FDA shortage list?

No. Neomycin Sulfate, Polymyxin B and Hydrocortisone is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (3 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.